Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL5832915 | 0.97 | KDM4E (0.71) | KDM4EALDH1A1HPGDPPARGPPARA | |
| SCHEMBL27630799 | 0.88 | KDM4E (0.57) | KDM4EALDH1A1HPGDPPARGPPARA | |
| SCHEMBL893027 | 0.86 | KDM4E (1.00) | KDM4EHPGDPPARGPPARANPC1 | |
| SCHEMBL13633903 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDPPARGPPARA | |
| SCHEMBL4415685 | 0.80 | NPC1 (0.49) | KDM4EALDH1A1HPGDPPARGPPARA | |
| SCHEMBL4392581 | 0.80 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL20022402 | 0.79 | IKBKB (0.58) | KDM4EALDH1A1HPGDIKBKBNPC1 | |
| SCHEMBL3800800 | 0.79 | KDM4E (0.80) | KDM4EALDH1A1HPGDPPARGPPARA | |
| SCHEMBL6817027 | 0.77 | KDM4E (0.64) | KDM4EHPGDPPARGPPARANPC1 | |
| SCHEMBL5099375 | 0.77 | KDM4E (0.72) | KDM4EALDH1A1HPGDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| US-7560548-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-07-14 | — | — | US | disclosed |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-7101882-B2 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | KDM4E 2863/4885ALDH1A1 3130/4885HPGD 2765/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | KDM4E 3596/4885ALDH1A1 1003/4885HPGD 1236/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | KDM4E 3869/4885ALDH1A1 1688/4885HPGD 2274/4885 |
| US-20090163495-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ARG1, ARG2, NFKBIA | KDM4E 3869/4885ALDH1A1 1688/4885HPGD 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.